Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis

Int J Rheum Dis. 2023 Dec;26(12):2603-2606. doi: 10.1111/1756-185X.14835. Epub 2023 Jul 11.

Authors

Grigorios T Sakellariou¹, Maria Konsta², Ioanna Katsigianni¹, Dimitrios Deligeorgakis¹, Dimitrios Zisopoulos¹, Periklis Vounotrypidis¹

Affiliations

¹ Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece.
² Department of Rheumatology, Sismanoglio Hospital, Athens, Greece.

PMID: 37432022
DOI: 10.1111/1756-185X.14835

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Osteogenesis
Spondylitis, Ankylosing* / diagnosis
Spondylitis, Ankylosing* / drug therapy

Substances

secukinumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal